Disease: Acute COVID-19

Geismar

United Kingdom
|
2020-2022
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Community
  • Household
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Maglione

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

FIDO

United Kingdom Ireland
|
2022-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

MIViral

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

RESP-VIR

Italy
|
2025-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Hospital
  • Non-hospital health centre
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Parainfluenza Virus
  • Metapneumovirus

BUCOSS RSV 60+

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

PAPI Study

Germany
|
2021
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Human metapneumovirus

COVID COHORT – SPAIN

Spain
|
2020-2025
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Blood sample
  • PBMC
  • Whole blood

EuCARE-SCHOOLS

Italy Portugal Mexico
|
2022-2024
  • Adults (18-64 years)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Community
  • SARS-CoV-2
  • Nasopharyngeal swab
  • Non pharmacological intervention

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab